Successful Drug Discovery, Volume 5

4 Chapter 4Figure 4.1 Schematic representation of the mechanism of action of SGLT2 inhi...Figure 4.2 Structure of the marketed gliflozins or candidates in phase III c...Figure 4.3 Structure of the dual inhibitors phlorizin and licogliflozin, and...Scheme 4.1 The first synthesis of dapagliflozin developed by Washburn and co...Scheme 4.2 Synthesis of dapagliflozin ( 1) developed by Gou and coworkers [19...Scheme 4.3 Synthesis of dapagliflozin developed by Walczak and coworkers [20...Scheme 4.4 Synthetic route of dapagliflozin reported by Yu and coworkers [22...Scheme 4.5 Synthetic approach of sotagliflozin ( 2) developed by Goodwin et a...Scheme 4.6 Synthetic pathway to sotagliflozin ( 2) developed by Li and cowork...Scheme 4.7 Synthesis of empagliflozin ( 3) following the synthetic pathway re...Scheme 4.8 Synthesis of benzyl‐protected empagliflozin 45by reaction of iod...Scheme 4.9 Synthesis of empagliflozin analogue 54[28].Scheme 4.10 Synthetic route of bexafloglizin ( 4) developed by Sun and cowork...Scheme 4.11 Synthesis of luseogliflozin ( 5) by Kakinuma et al. [32]. (a) Syn...Scheme 4.12 Tofogliflozin synthesis reported by Chugai Pharmaceuticals [34]....Scheme 4.13 Preparation of the tofogliflozin's aglycone [38].Scheme 4.14 Preparation of glycone 90[38].Scheme 4.15 Synthesis of tofogliflozin ( 6) [38].Scheme 4.16 Synthesis of ertugliflozin ( 7) carried out by Triantakonstanti e...Scheme 4.17 Synthesis of ipragliflozin ( 8) by Zhou and coworkers [45]. Licen...Scheme 4.18 Canagliflozin ( 9) synthesis according to Nomura et al. [48].Scheme 4.19 Canagliflozin ( 9) synthesis according to Nakamura and coworkers ...Scheme 4.20 Patented synthesis by Optimus Drugs Pvt. Ltd of canagliflozin ( 9Scheme 4.21 Improved process for the synthesis of canagliflozin ( 9) develope...Scheme 4.22 Total synthesis of remogliflozin etabonate ( 10) by Kobayashi et ...Figure 4.4 Benefits versus risks of treatment with SGLT2 inhibitors.

5 Chapter 5Figure 5.1 T cell receptor and costimulatory activation or inhibition of T c...Figure 5.2 A comparison of the basic structure of engineered TCR and CAR con...Figure 5.3 CAR design and evolution. CAR molecules consist of an extracellul...Figure 5.4 Cellular kinetics of CART19 cells in leukemia patients. CART19 ex...Figure 5.5 Vein‐to‐vein workflow for the clinical manufacture of lentiviral ...Figure 5.6 Potential mechanisms of CAR T cell therapy in cancer. Cancer cell...

6 Chapter 6Figure 6.1 Structures of selected small‐molecule CGRP‐RA. (a) Telcagepant, (...Figure 6.2 Comparison of the placebo subtracted headache improvement at two ...Figure 6.3 Efficacy at early time points in the phase 2 chronic migraine tri...

7 Chapter 7Figure 7.1 (a) FVIIIa consists of the A1 subunit, the A2 subunit, and the li...Figure 7.2 Flow of process to identify the lead bispecific antibody (BS15). ...Figure 7.3 Multidimensional optimization flow to generate the bispecific ant...Figure 7.4 Schematic illustration of the emicizumab molecule. CDR, complemen...

8 Chapter 8Figure 8.1 Generation of R(−)‐2‐hydroxyglutarate by mIDH1.Figure 8.2 Structural Analysis of WT vs mIDH1 Proteins. Left panels show Wi...Figure 8.3 Inhibition of the mIDH1 R132H enzyme reaction via a diaphorase/re...Figure 8.4 HTS Hit 1and retrosynthetic analysis of the 2, N ‐diphenyl glycine...Figure 8.5 Key structural elements accounting for the enzymatic activity of ...Scheme 8.1 (a) Synthesis of derivatives of 2, N ‐diphenyl glycine via the Ugi ...Figure 8.6 Tumor 2‐HG inhibition following one (a) and three BID doses (b) o...Figure 8.7 Tumor 2‐HG concentration following single QD dose of AGI‐14100 in...Scheme 8.2 Synthesis of AG‐120 via the Ugi reaction ([20]; supporting inform...Figure 8.8 Tumor 2‐HG concentration and AG‐120plasma concentration fo...Figure 8.9 Ex vivo treatment with AG‐120reduces 2HG in primary patien...Figure 8.10 Ex vivo treatment with AG‐120increases differentiation ma...Figure 8.11 “Swim plot” showing each patient and treatment outcome of the be...

9 Chapter 9Figure 9.1 A simplified model of the cell cycle showing cyclin‐CDK complexes...Figure 9.2 The CDK4/6 pathway and oncogenic mutations.Figure 9.3 Structure‐based optimization of a fragment hit.Figure 9.4 Evolution of a fragment‐based series.Figure 9.5 Optimization of an existing kinase asset leading to ribociclib.Figure 9.6 Crystal structure of ribociclib bound to cyclin D1‐CDK4: ribocicl...Figure 9.7 Ribociclib arrests the cell cycle exclusively in G1: JeKo‐1 mantl...Figure 9.8 Ribociclib given orally once daily causes dose‐dependent tumor re...Figure 9.9 Activity of ribociclib in combination with the aromatase inhibito...

1 Title Page Successful Drug Discovery Volume 5 Edited by János Fischer Christian Klein Wayne E. Childers

2 Table of Contents

3 Begin Reading

4 Index

5 WILEY END USER LICENSE AGREEMENT

1 iv

2 xi

3 xiii

4 xiv

5 1

6 3

7 4

8 5

9 6

10 7

11 8

12 9

13 10

14 11

15 12

16 13

17 14

18 15

19 16

20 17

21 18

22 19

23 20

24 21

25 22

26 23

27 24

28 25

29 26

30 27

31 28

32 29

33 30

34 31

35 32

36 33

37 34

38 35

39 36

40 37

41 38

42 39

43 40

44 41

45 42

46 43

47 44

48 45

49 46

50 47

51 48

52 49

53 50

54 51

55 52

56 53

57 54

58 55

59 56

60 57

61 58

62 59

63 60

64 61

65 62

66 63

67 64

68 65

69 66

70 67

71 68

72 69

73 70

74 71

75 72

76 73

77 74

78 75

79 76

80 77

81 78

82 79

83 80

84 81

85 82

86 83

87 84

88 85

89 87

90 89

91 90

92 91

93 92

94 93

95 94

96 95

97 96

98 97

99 98

100 99

101 100

102 101

103 103

104 104

105 105

106 106

107 107

108 108

109 109

110 110

111 111

112 112

113 113

114 114

115 115

116 116

117 117

118 118

119 119

120 120

121 121

122 122

123 123

124 124

125 125

126 126

127 127

128 128

129 129

130 130

131 131

132 132

133 133

134 134

135 135

136 136

137 137

138 138

139 139

140 140

141 141

142 142

143 143

144 144

145 145

146 146

147 147

148 148

149 149

150 150

151 151

152 152

153 153

154 154

155 155

156 156

157 157

158 159

159 160

160 161

161 162

162 163

163 164

164 165

165 166

166 167

167 168

168 169

169 170

170 171

171 172

172 173

173 174

174 175

175 176

176 177

177 178

178 179

179 180

180 181

181 182

182 183

183 184

184 185

185 186

186 187

187 188

188 189

189 190

190 191

191 192

192 193

193 194

194 195

195 196

196 197

197 198

198 199

199 200